E-I

General Information


DRACP ID  DRACP01982

Peptide Name   E-I

Sequence  EIIKKIIKKIIKKI

Sequence Length  14

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP Membrane-targeted



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
Jurkat Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia Leukemia IC50=23 µM MTT assay 24 h 1

Hemolytic Activity  Human erythrocytes: 5% Hemolysis=300 µM; Human erythrocytes: 7% Hemolysis=500 µM

Normal (non-cancerous) Cytotoxicity  Human chondrocytes-articular cells Hca: 23% Killing=40 µM

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  DRACP01982

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C83H158N20O17

Absent amino acids  ACDFGHLMNPQRSTVWY

Common amino acids  I

Mass  194037

Pl  11.1

Basic residues  6

Acidic residues  1

Hydrophobic residues  7

Net charge  5

Boman Index  -567

Hydrophobicity  32.86

Aliphatic Index  195

Half Life 
  Mammalian: 4.4 hour
  Yeast: >20 hour
  E.coli: >10 hour

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  0

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 27644109

Title  Surface Physical Activity and Hydrophobicity of Designed Helical Peptide Amphiphiles Control Their Bioactivity and Cell Selectivity

Doi 10.1021/acsami.6b08297

Year  2016

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DBAASP ID  DBAASPS_14056

DRACP is developed by Dr.Zheng's team.